Literature Citations

Shaheen Khan , Saad A. Khan, Xin Luo, Farjana J. Fattah, Jessica Saltarski, Yvonne Gloria-McCutchen , Rong Lu, Yang Xie, Quan Li, Edward Wakeland and David E. Gerber

Immune Dysregulation in Cancer Patients Developing Immune-Related Adverse Events

Up to 40% of cancer patients on immune checkpoint inhibitors develop clinically significant immune-related adverse events (irAEs). The role of host immune status and function in predisposing patients to the development of irAEs remains unknown

David Hsiehchen, MD; Mary K. Watters, MD; Rong Lu, PhD; Yang Xie, PhD; David E. Gerber, MD

Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors

Toxic effects of conventional chemotherapy and molecularly targeted cancer therapies are generally well defined and occur at predictable points. By contrast, owing to their heterogeneous manifestations, unpredictable timing, and clinical overlap with other conditions, immune-related adverse events (irAE) may be more difficult to diagnose and characterize.

Shaheen Khan, Mitchell S. von Itzstein, Rong Lu, Bonnie L. Bermas, David R. Karp, Saad A. Khan, Farjana J. Fattah, Jason Y. Park, Jessica M. Saltarski, Yvonne GloriaMcCutchen, Yang Xie, QuanZhen Li, Edward K. Wakeland, David E. Gerber,

Late‐Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor–Induced Raynaud's‐Like Phenomenon

Immune checkpoint inhibitor (ICI)-induced immune-related adverse events (irAEs) may affect almost any organ system and occur at any point during therapy. Autoantibody analysis may provide insight into the mechanism, nature, and timing of these events.

Amrit S Gonugunta ,Mitchell S von Itzstein, Hong MuMosley , Farjana Fattah, J David Farrar, Angela Mobely, Sawsan Rashdan, Sunny Lai, Salman F Bhai, Bonnie L Bermas,David Karp, Quan-Zhen Li, Edward K Wakeland, David E Gerber

Humoral and Cellular Correlates of a Novel Immune-Related Adverse Event and its Treatment

While immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer, associated toxicities termed immune-related adverse events (irAE) occur in a substantial proportion of patients. These autoimmune events may affect almost any organ system.

Jared Ostmeyer, Jason Y Park, Mitchell S von Itzstein, David Hsiehchen, Farjana Fattah, Mary Gwin, Rodrigo Catalan, Shaheen Khan, Prithvi Raj, Edward K Wakeland, Yang Xie, David E Gerber

T-cell tolerant fraction as a predictor of immune-related adverse events

Background Immune checkpoint inhibitor (ICI) therapies may cause unpredictable and potentially severe autoimmune toxicities termed immune-related adverse events (irAEs). Because T cells mediate ICI effects, T cell profiling may provide insight into the risk of irAEs.